- Home
- VATE vs PSNL Comparison
VATE vs PSNL Comparison
Compare VATE & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VATE | PSNL |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.8M | 1.4B |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | VATE | PSNL |
|---|---|---|
| Price | $7.73 | $16.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 646.9K | ★ 3.4M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,246,000,000.00 | $69,648,000.00 |
| Revenue This Year | N/A | $15.34 |
| Revenue Next Year | N/A | $41.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 12.55 | N/A |
| 52 Week Low | $3.75 | $4.65 |
| 52 Week High | $21.30 | $18.89 |
Technical Indicators
Market Signals| Indicator | VATE | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 44.84 | 62.42 |
| Support Level | $4.38 | $7.36 |
| Resistance Level | $8.20 | N/A |
| Average True Range (ATR) | 0.76 | 0.79 |
| MACD | 0.19 | 0.24 |
| Stochastic Oscillator | 40.70 | 58.25 |
Price Performance
Historical ComparisonAbout VATE INNOVATE Corp.
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.